I ricercatori hanno aggiornato le linee guida per la pratica clinica su […]
Search Results for: L’eparina inibisce la proteina spike del virus SARS-Cov-2
Here's what we've found for you
Spotlight: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating the risk of HBVr. In select cases, clinical monitoring without antiviral prophylaxis is sufficient for managing the risk of HBVr. This clinical practice guideline update aims to inform frontline health care practitioners by providing evidence-based practice recommendation for the management of HBVr in at-risk individuals.
Global vaccine research and application hotspots and trends: a systematic bibliometric analysis based on SCIE highly cited papers
Objectives
COVID-19, a public health emergency affecting the world in 2019, not only greatly promoted the development and application of vaccines but also effectively shortened the publishing time of scientific papers. In view of these facts, the current situation, status, problems and development trends of vaccine research and application were explored through bibliometric analysis of highly cited papers in the vaccine field within the time frame of 2014–2024, and the countries, institutions, authors, funding agencies and other relevant information that contributed most to vaccine research and application were summarised.
Design
Bibliometric analysis through data analysis and visual mapping.
Data sources
Scientific articles.
Data extraction and synthesis
‘Vaccine’ and ‘vaccines’ were used in the WoS database to retrieve the publications and to adequately collect the data; Microsoft Excel was used for data analysis; and VOSviewer was used for visual description of data. Overall publication trends, countries, institutions and funding agencies, authors and articles, journals and languages, and research areas and co-occurrence keywords were analysed by bibliometrics.
Results
A total of 3258 highly cited papers were published in the field of vaccines in the past decade, from 735 different journals. With the COVID-19 pandemic in 2019, the number of highly cited papers in the field of vaccine research increased significantly from 2020 to 2024, accounting for 76.12%. The number of highly cited papers for vaccines peaked in 2021 and 2022, followed by a rapid decline. Highly cited papers came from 7133 institutions in 153 countries, and the most influential country in the field of vaccines was the USA, which published 1733 highly cited papers, accounting for 53.19% of the highly cited papers. The top 15 institutions with the largest influence were all from the USA or UK with 2567 published papers in total, accounting for 78.79% of highly cited papers. 4787 funding agencies were recognised in funding 2368 highly cited papers. A total of 30 926 authors in 90 research areas contributed significantly to global vaccine research. The most highly cited paper was ‘Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine’ from the New England Journal of Medicine, which was cited 9435 times in total. Among the 9848 co-occurrence keywords, COVID-19 (including SARS-CoV-2, 2019-COVID and SARS2) was the most frequently co-occurrence keyword. It appeared in 1720 articles, accounting for 52.79%, indicating that COVID-19 was the most popular study in the last decade.
Conclusions
This study visualised the research and application of vaccines in the world from the perspective of papers output, drew the knowledge map and identified the important research hotspots and development trends in the vaccine field in the recent 10 years (2014–2024), which is helpful for Centres for Disease Control and Prevention, clinicians, researchers and health policymakers to better understand the research status and problems in vaccine research and application and predict its future development direction.
Mycoplasma pneumoniae in U.S. Schools: Trends and the Upshot
M. pneumoniae respiratory infections in a large southern U.S. school system in 2024 showed a spike in infections and absenteeism among students and staff.
Marburg Virus Disease in Rwanda — Centering Both Evidence and Equity
New England Journal of Medicine, Ahead of Print.
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial
Introduction
Despite repeated vaccinations against SARS-CoV-2 virus, patients who are immunocompromised remain at very high risk of catching SARS-CoV-2 virus and becoming unwell. AZD7442 (Evusheld) is a long-acting monoclonal antibody treatment that has been shown in clinical trials to prevent SARS-CoV-2 infection for up to a year after a single dose. Vaccines require a healthy immune system to generate protective immunity. AZD7442 may prevent SARS-CoV-2 infection in immunocompromised individuals that may not have responded to repeated vaccinations against SARS-CoV-2 virus. Unlike vaccinations, AZD7442 reaches effective levels within the body a few hours after a single dose. The RAPID-PROTECTION trial will determine the levels of immune protection that AZD7442 offers patients at the very highest risk of SARS-CoV-2 infection and whether this protection can be further enhanced by repeated vaccination against SARS-CoV-2 virus.
Methods
RAPID-PROTECTION is a multicentre, interventional and open-label adaptive platform trial that aims to recruit 350 immunocompromised participants across five UK centres. Participants will be administered AZD7442 on day 0 followed by a SARS-CoV-2 vaccination 28 days later. Participants will be randomised (1:1) to the Moderna vaccine or Pfizer/BioNTech vaccine. Participant samples will be taken at baseline and at multiple timepoints after the administration of AZD7442.
Analysis
The participant samples will be analysed to measure the function and magnitude of SARS-CoV-2 specific antibody and T-cell responses at baseline and at multiple timepoints after the administration of AZD7442. The immunological effect of the study interventions will be determined by comparison of the results of immunological assessments at baseline and subsequent timepoints.
Ethics and dissemination
The trial protocol was approved by the research ethics committee of the National Health Service (reference 22/HRA/0359), Health Research Authority and Health and Care Research Wales on 25 July 2022. Findings will be disseminated through peer-reviewed journals and presented at scientific conferences.
Trial registration number
ISRCTN53507177.
Porcine-derived pancreatic enzyme replacement therapy linking to chronic hepatitis E: broad implications
We read with interest the recent work by Thornton et al, which described three cases of chronic hepatitis E in persons with cystic fibrosis (pwCF) after lung transplantation.1 Because most pwCF took porcine-derived pancreatic enzyme replacement therapy (PERT), the authors suspected PERT as a plausible source of transmitting hepatitis E virus (HEV) to these patients. Alarmingly, the authors found that 44% of PERT capsules were positive for HEV viral RNA.1 Although there remains a knowledge gap whether the viral components presented in PERT are actually infectious, which can be further assessed for example by using experimental models, the intriguing findings from this study do bear broad implications (figure 1). Currently, PERT is indicated for treating exocrine pancreatic insufficiency due to cystic fibrosis or other conditions in both paediatric and adult patients, and thus the overall size of this patient population is substantial.
Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?
Recently, in Canada, Thornton et al observed a higher proportion of anti-hepatitis E virus (HEV) IgG among persons with cystic fibrosis having received (20.7%) or not (19.3%) a lung transplantation compared with a non-cystic fibrosis population (10.7%).1 In order to understand the difference in the seropositivity rate between these populations, they focused their research on the use of pancreatic enzyme replacement therapy (PERT).1 Indeed, pancreatic insufficiency is quite common in patients with cystic fibrosis, requiring PERT. PERT is porcine derived. Pork is one of the main reservoirs of HEV.2 Zoonotic transmission of viruses through PERT was previously recognised.3 Thornton et al detected HEV RNA in 44% of PERT capsules obtained from different formulations and produced by four different manufacturers.1 In their study, 3 out of 29 lung transplant patients with cystic fibrosis have detectable HEV RNA and developed chronic…
Casi di afta, Gb sospende l'importazione delle carni tedesche
Stop a carni bovine,suine e ovine per contenere diffusione virus
New Research Suggests Increased Risk of Some Autoimmune Disorders After COVID-19
New research suggests SARS-CoV-2 infection may increase the long-term risk of autoimmune or autoinflammatory connective tissue disorders.
First H5N1 Bird Flu Infections in Pigs Raises Concerns
The US Department of Agriculture (USDA) recently identified the nation’s first cases of avian influenza A(H5N1) virus, or H5N1 bird flu, in swine. The infected pigs were 2 of 5 on a noncommercial farm in Oregon that shared water, housing, and equipment with infected poultry, which likely facilitated the virus’ transmission.
Identifying people with post-COVID condition using linked, population-based administrative health data from Manitoba, Canada: prevalence and predictors in a cohort of COVID-positive individuals
Objective
Many individuals exposed to SARS-CoV-2 experience long-term symptoms as part of a syndrome called post-COVID condition (PCC). Research on PCC is still emerging but is urgently needed to support diagnosis, clinical treatment guidelines and health system resource allocation. In this study, we developed a method to identify PCC cases using administrative health data and report PCC prevalence and predictive factors in Manitoba, Canada.
Design
Cohort study.
Setting
Manitoba, Canada.
Participants
All Manitobans who tested positive for SARS-CoV-2 during population-wide PCR testing from March 2020 to December 2021 (n=66 365) and were subsequently deemed to have PCC based on International Classification of Disease-9/10 diagnostic codes and prescription drug codes (n=11 316). Additional PCC cases were identified using predictive modelling to assess patterns of health service use, including physician visits, emergency department visits and hospitalisation for any reason (n=4155).
Outcomes
We measured PCC prevalence as % PCC cases among Manitobans with positive tests and identified predictive factors associated with PCC by calculating odds ratios with 95% confidence intervals, adjusted for sociodemographic and clinical characteristics (aOR).
Results
Among 66 365 Manitobans with positive tests, we identified 15 471 (23%) as having PCC. Being female (aOR 1.64, 95% CI 1.58 to 1.71), being age 60–79 (aOR 1.33, 95% CI 1.25 to 1.41) or age 80+ (aOR 1.62, 95% CI 1.46 to 1.80), being hospitalised within 14 days of COVID-19 infection (aOR 1.95, 95% CI 1.80 to 2.10) and having a Charlson Comorbidity Index of 1+ (aOR 1.95, 95% CI 1.78 to 2.14) were predictive of PCC. Receiving 1+ doses of the COVID-19 vaccine (one dose, aOR 0.80, 95% CI 0.74 to 0.86; two doses, aOR 0.29, 95% CI 0.22 to 0.31) decreased the odds of PCC.
Conclusions
This data-driven approach expands our understanding of the prevalence and epidemiology of PCC and may be applied in other jurisdictions with population-based data. The study provides additional insights into risk and protective factors for PCC to inform health system planning and service delivery.
Individuato un nuovo potenziale obiettivo per superare la resistenza al cancro al seno
Un nuovo studio dell’University of Cincinnati Cancer Center ha identificato un […]
I traumi alla testa aprono la porta ad Alzheimer e Parkinson
Perché risvegliano virus latenti dannosi
Enhancing Neuron Activity Promotes Functional Recovery by Inhibiting Microglia-Mediated Synapse Elimination After Stroke
Stroke, Ahead of Print. BACKGROUND:Activating glutamatergic neurons in the ipsilesional motor cortex can promote functional recovery after stroke. However, the underlying molecular mechanisms remain unclear. Clarifying key molecular mechanisms involved in recovery could help understand the development of neuromodulation strategies after stroke.METHODS:Adeno-associated virus 2/9-CamKIIa-hM3Dq-mCherry was injected into ipsilesional motor cortex by stereotaxic in the photothrombotic stroke model. Starting from the third day after the stroke, male mice were injected intraperitoneally with clozapine-N-oxide every day to activate excitatory neurons. C1q-blocking antibody and annexin V were used to inhibit C1q and exposed phosphatidylserine (EPS), respectively. The cylinder test and grid-walking test were performed to evaluate functional recovery. The potential molecular mechanisms of excitatory neuronal activation on microglia-mediated synaptic pruning after stroke by immunofluorescence, real-time polymerase chain reaction, Western blotting, and RNA sequencing.RESULTS:Activating excitatory neurons significantly promoted functional recovery and inhibited microglia-mediated synaptic pruning after stroke. Furthermore, it decreased EPS and C1q levels in synapses. On the contrary, inhibiting excitatory neurons aggravated functional defects, promoted microglia-mediated synaptic pruning, and increased EPS and C1q levels in synapses. Selective blocking of EPS repressed C1q tagging of synapses and microglia-mediated synaptic pruning and improved functional recovery. Meanwhile, blocking EPS markedly rescued synaptic density, and motor function deteriorated by chemogenetic inhibition. In addition, C1q-blocking antibody prevented phosphatidylserine engulfment by microglia.CONCLUSIONS:Together, these data provide mechanistic insight into microglia-mediated synapse pruning after neuronal activation after stroke and identify the role of C1q binding to EPS in stroke treatment during the repair phase.